國藥控股股份有限公司 董事長 香港交易及結算所有限公司及香港聯合交易所有限公司對本通告之內容概不負責 , 對其準確性或完 整性亦不發表任何聲明 , 並明確表示 , 概不就因本通告全部或任何部分內容而產生或因倚賴該等內容 而引致之任何損失承擔任何責任。 ( 於中華人民共和國註冊成立之股份有限公司 , 在香港以國控股份有限公司之名稱經營業務 ) (股份代號 :01099) 董事會會議通告 國藥控股股份有限公司(「本公司」)董事會(「董事會」)謹此宣佈，將於 2025 年 10 月 24 日 (星期五)舉行董事會會議，藉以考慮及批准(其中包括)本公司及其附屬公司截至 2025 年 9 月 30 日止九個月之未經審核季度業績。 承董事會命 * 本公司以其中文名稱及英文名稱「 Sinopharm Group Co. Ltd. 」根據香港公司條例註冊為非香港公司。 趙炳祥 中國，上海 2025年10 月10日 於本通告日期，執行董事為連萬勇先生及孫京林先生；非執行董事為趙炳祥先生、陳啟宇先生、祖 敬先生、邢永剛先生、陳玉卿先生、文德鏞先生及馮蓉麗女士；獨立非執行董事為李培育先生、吳 德龍先生、俞衛鋒先生、石晟昊先生及陳威 ...

| 股份代號: | 01099 | | --- | --- | | 上市法國名稱: | 國藥控股股份有限公司 - | | 日期 (日 / 月 / 年): | 10/09/2025 - 10/10/2025 | 格隆汇10月10日丨根据联交所最新权益披露资料显示，2025年10月2日，国药控股(01099.HK)获Lazard Asset Management LLC在场内以每股均价18.61港元增 持23.52万股，涉资约437.71万港元。 增持后，Lazard Asset Management LLC最新持股数目为134,318,616股，持股比例由9.99%上升至10.01%。 | 表 | 大股東/董事/最高行政人員名稱 作出披露的 買入 / 賣出或涉及的股每股的平均價 | | 持有權益的股份數目 佔己發行的 有關事件的日 | | | --- | --- | --- | --- | --- | | | | | 請參閱上述*註解)有投票權股 (日 / 月 / 年) | | | | | | 向自分可 | | | CS20251008E00547 | Lazard Asset Management 1101( ...

香港联交所最新资料显示，10月2日，Lazard Asset Management LLC增持国药控股(01099)23.52万股，每 股作价18.61港元，总金额约为437.71万港元。增持后最新持股数目约为1.34亿股，最新持股比例为 10.01%。 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年9月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 國藥控股股份有限公司 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01099 | 說明 | H股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 1,341,810,740 | RMB | | 1 | RMB | | 1,341,810,740 | | 增加 / 減少 (-) | | | | | | | RMB | | | | 本月底結存 | | | 1,341,810,740 | RMB | | 1 | RMB | | 1,341,810,740 | | 2. 股份分類 | 普通股 | 股份類別 | ...

(资料图片) 格隆汇9月30日丨根据联交所最新权益披露资料显示，2025年9月24日，国药控股(01099.HK)遭 Lazard Asset Management LLC在场内以每股均价18.48港元减持54.64万股，涉资约1009.75万港元。 标签： 财经频道 财经资讯 减持后，Lazard Asset Management LLC最新持股数目为134,018,253股，持股比例由10.03%下降至 9.99%。 ...

Group 1 - Lazard Asset Management LLC reduced its stake in China National Pharmaceutical Group (国药控股) by selling 546,400 shares at an average price of HKD 18.48 per share, totaling approximately HKD 10.1 million [1] - After the sale, Lazard's total shareholding decreased to 134,018,253 shares, representing a reduction in ownership from 10.03% to 9.99% [1]

来源：新浪港股 香港联交所最新资料显示，9月24日，Lazard Asset Management LLC减持国药控股（01099）54.64万 股，每股均价18.48港元，总金额约为1009.75万港元。减持后最新持股数目约为1.34亿股，最新持股比 例为9.99%。 ...

香港联交所最新资料显示，9月24日，Lazard Asset Management LLC减持国药控股(01099)54.64万股，每 股均价18.48港元，总金额约为1009.75万港元。减持后最新持股数目约为1.34亿股，最新持股比例为 9.99%。 ...

Group 1 - Lazard Asset Management LLC reduced its holdings in China National Pharmaceutical Group (01099) by 546,400 shares at an average price of HKD 18.48 per share, totaling approximately HKD 10.0975 million [1] - After the reduction, Lazard's latest shareholding stands at approximately 134 million shares, representing a holding percentage of 9.99% [1]

Core Viewpoint - The report maintains a "Buy" rating for China National Pharmaceutical Group (国药控股) with a target price of HKD 21.3, highlighting short-term performance pressure but long-term benefits from aging trends and policy integration [1] Financial Performance - In H1 2025, the company reported revenue of CNY 286.04 billion, a decrease of 2.95% year-on-year, with a gross profit of CNY 20.35 billion, down 7.28% [1] - The overall gross margin was under pressure at 7.11%, a decline of 0.34% year-on-year, while net profit fell to CNY 5.337 billion, down 9.53% [1] - Profit attributable to equity holders was CNY 3.47 billion, a decrease of 6.43%, but effective cost control led to a reduction in selling, administrative, and financial expense ratios [1] Pharmaceutical Distribution Segment - The pharmaceutical distribution segment generated revenue of CNY 218.53 billion, down 3.52% year-on-year, with an operating profit margin of 2.58%, a decline of 0.17 percentage points [2] - The company is focusing on core hospital markets and grassroots medical needs, which has contributed to overall market share growth despite revenue decline [2] - The strategic shift to reduce low-margin revenue has improved supply chain efficiency and compliance [2] Medical Device Distribution - Revenue from the medical device distribution business was CNY 57.05 billion, down 2.46%, with an operating profit margin of 1.92%, a decrease of 0.33 percentage points [2] - The company is optimizing channel structures and has added new projects to enhance revenue, with SPD projects driving a 13% year-on-year increase in device revenue [2] Retail Pharmacy Segment - The retail pharmacy segment achieved revenue of CNY 17.16 billion, a growth of 3.6%, with an operating profit margin of 2.68%, up 1.13 percentage points [3] - As of June 30, 2025, the total number of Guoda pharmacies was 8,591, a net decrease of 978 stores, focusing on quality improvement and network optimization [3] - The net profit of the retail segment saw a significant increase of 215.8% year-on-year, driven by same-store sales growth in prescription and innovative drug support [3]